Anthera Pharmaceuticals Company Profile (NASDAQ:ANTH)

About Anthera Pharmaceuticals (NASDAQ:ANTH)

Anthera Pharmaceuticals logoAnthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ANTH
  • CUSIP: N/A
  • Web: www.anthera.com
Capitalization:
  • Market Cap: $16.83 million
  • Outstanding Shares: 10,076,000
Average Prices:
  • 50 Day Moving Avg: $1.31
  • 200 Day Moving Avg: $1.09
  • 52 Week Range: $0.30 - $4.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.44
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.24 per share
  • Price / Book: 6.96
Profitability:
  • EBIDTA: ($55,830,000.00)
  • Return on Equity: -202.44%
  • Return on Assets: -131.12%
Debt:
  • Current Ratio: 2.45%
  • Quick Ratio: 2.45%
Misc:
  • Average Volume: 2.04 million shs.
  • Beta: 1.16
  • Short Ratio: 2.27
 

Frequently Asked Questions for Anthera Pharmaceuticals (NASDAQ:ANTH)

What is Anthera Pharmaceuticals' stock symbol?

Anthera Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANTH."

When did Anthera Pharmaceuticals' stock split? How did Anthera Pharmaceuticals' stock split work?

Shares of Anthera Pharmaceuticals reverse split on Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 28th 2017. An investor that had 100 shares of Anthera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

How were Anthera Pharmaceuticals' earnings last quarter?

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) announced its quarterly earnings results on Wednesday, May, 10th. The company reported ($2.03) earnings per share for the quarter, missing analysts' consensus estimates of ($1.47) by $0.56. View Anthera Pharmaceuticals' Earnings History.

Where is Anthera Pharmaceuticals' stock going? Where will Anthera Pharmaceuticals' stock price be in 2017?

6 analysts have issued 1 year target prices for Anthera Pharmaceuticals' shares. Their forecasts range from $2.25 to $24.00. On average, they anticipate Anthera Pharmaceuticals' stock price to reach $11.26 in the next twelve months. View Analyst Ratings for Anthera Pharmaceuticals.

What are analysts saying about Anthera Pharmaceuticals stock?

Here are some recent quotes from research analysts about Anthera Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company's clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. " (5/8/2017)
  • 2. Jefferies Group LLC analysts commented, "Following narrow miss in Sollpura SOLUTION study in late 2016, ANTH has included key learnings into the Ph. III RESULT study, to start soon and data by early 2018. Decision to discontinue B-mod in lupus is not surprising due to negative CHABLIS data in Q4 2016 and conserves cash. With $21M in cash and two ATMs, ANTH is positioned to fund operations through RESULT data. We expect shares to remain range-bound NT due to few 2017 data catalysts. Lower PT to $0.80." (3/6/2017)

Are investors shorting Anthera Pharmaceuticals?

Anthera Pharmaceuticals saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 10,669,429 shares, an increase of 13.9% from the April 13th total of 9,365,054 shares. Based on an average daily trading volume, of 1,747,316 shares, the days-to-cover ratio is currently 6.1 days.

Who are some of Anthera Pharmaceuticals' key competitors?

Who are Anthera Pharmaceuticals' key executives?

Anthera Pharmaceuticals' management team includes the folowing people:

  • Paul F. Truex, Executive Chairman of the Board
  • Craig Thompson, President, Chief Executive Officer, Chief Operating Officer, Director
  • May Liu, Senior Vice President - Finance and Administration, Principal Accounting Officer
  • Klara A. Dickinson, Chief Regulatory Officer, Senior Vice President
  • William R. Shanahan Jr. M.D. J.D., Chief Medical Officer
  • Brent Furse, Director
  • Christopher S. Henney Ph.D., Independent Director
  • Brian R. Mueller, Independent Director
  • Philip T Sager, Independent Director
  • David E. Thompson, Independent Director

Who owns Anthera Pharmaceuticals stock?

Anthera Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include SABBY MANAGEMENT, LLC (8.06%), Vanguard Group Inc. (0.00%), Sabby Management LLC (27.79%), UBS Group AG (0.00%), Goldman Sachs Group Inc. (5.69%) and Geode Capital Management LLC (0.00%). Company insiders that own Anthera Pharmaceuticals stock include Colin Hislop and Debra Odink. View Institutional Ownership Trends for Anthera Pharmaceuticals.

Who bought Anthera Pharmaceuticals stock? Who is buying Anthera Pharmaceuticals stock?

Anthera Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC, Vanguard Group Inc., Goldman Sachs Group Inc., Geode Capital Management LLC and UBS Group AG. View Insider Buying and Selling for Anthera Pharmaceuticals.

How do I buy Anthera Pharmaceuticals stock?

Shares of Anthera Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anthera Pharmaceuticals' stock price today?

One share of Anthera Pharmaceuticals stock can currently be purchased for approximately $1.67.


MarketBeat Community Rating for Anthera Pharmaceuticals (NASDAQ ANTH)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  126 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  231
MarketBeat's community ratings are surveys of what our community members think about Anthera Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Anthera Pharmaceuticals (NASDAQ:ANTH) (?)
Ratings Breakdown: 4 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $11.26 (574.40% upside)

Analysts' Ratings History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Jefferies Group LLCReiterated RatingHold$2.25HighView Rating Details
12/29/2016Piper Jaffray CompaniesLower Price TargetOverweight$56.00 -> $10.80N/AView Rating Details
12/29/2016Citigroup IncDowngradeBuy -> NeutralN/AView Rating Details
12/29/2016HC WainwrightReiterated RatingBuy$80.00 -> $24.00N/AView Rating Details
12/28/2016SunTrust Banks, Inc.DowngradeBuy -> Hold$48.00 -> $8.00N/AView Rating Details
6/20/2016FBR & CoReiterated RatingHoldN/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Earnings by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)
Earnings History by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($1.47)($2.03)ViewN/AView Earnings Details
2/27/2017Q4 2016($3.25)($2.88)$0.10 millionViewN/AView Earnings Details
11/4/2016Q3($3.04)($4.88)$0.18 millionViewN/AView Earnings Details
8/9/2016Q2($2.48)($2.80)$0.15 millionViewN/AView Earnings Details
5/9/2016Q1($2.24)($2.32)$0.15 millionViewN/AView Earnings Details
3/10/2016Q4($2.24)($1.44)$0.31 million$1.92 millionViewN/AView Earnings Details
11/6/2015Q315($2.08)($2.32)$0.31 million$0.73 millionViewN/AView Earnings Details
8/10/2015Q2($2.24)($2.00)$0.29 millionViewN/AView Earnings Details
5/11/2015Q115($2.48)($2.24)$0.25 millionViewN/AView Earnings Details
3/16/2015Q4 2014($2.64)($2.56)ViewN/AView Earnings Details
11/14/2014Q3 2014($2.88)($2.48)ViewN/AView Earnings Details
7/28/2014Q2 2014($3.92)($2.72)ViewN/AView Earnings Details
5/13/2014Q114($4.48)($3.12)ViewN/AView Earnings Details
3/12/2014($3.76)($3.84)ViewN/AView Earnings Details
3/26/2013Q412($1.20)($0.88)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Anthera Pharmaceuticals (NASDAQ:ANTH)
2017 EPS Consensus Estimate: ($3.64)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.36)($0.16)($0.26)
Q2 20172($1.08)($1.06)($1.07)
Q3 20172($1.24)($1.04)($1.14)
Q4 20172($1.30)($1.03)($1.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Anthera Pharmaceuticals (NASDAQ:ANTH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Insider Ownership Percentage: 5.13%
Institutional Ownership Percentage: 50.87%
Insider Trades by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)
Institutional Ownership by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)
Insider Trades by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/13/2015Colin HislopinsiderSell12,500$5.31$66,375.00View SEC Filing  
11/11/2015Colin HislopInsiderSell5,000$5.38$26,900.00View SEC Filing  
10/12/2015Debra OdinkCTOSell1,205$6.15$7,410.75View SEC Filing  
6/24/2013David E ThompsonDirectorBuy12,500$0.53$6,625.00View SEC Filing  
5/31/2013Bogdan DziurzynskiDirectorBuy1,250$0.59$737.50View SEC Filing  
1/30/2013Orbimed Advisors LlcDirectorBuy712,500$0.66$470,250.00View SEC Filing  
1/25/2013Orbimed Advisors LlcDirectorBuy220,250$0.65$143,162.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Anthera Pharmaceuticals (NASDAQ:ANTH)
Latest Headlines for Anthera Pharmaceuticals (NASDAQ:ANTH)
Source:
DateHeadline
americanbankingnews.com logoAnthera Pharmaceuticals Inc (ANTH) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 22 at 6:20 PM
streetinsider.com logoForm 8-K Anthera Pharmaceuticals For: May 15 - StreetInsider.com
www.streetinsider.com - May 19 at 8:33 PM
seekingalpha.com logoAnthera continues down move, shares off 6% - Seeking Alpha
seekingalpha.com - May 19 at 8:33 PM
americanbankingnews.com logoAnthera Pharmaceuticals Inc (ANTH) Forecasted to Earn Q2 2017 Earnings of ($1.06) Per Share
www.americanbankingnews.com - May 19 at 7:28 AM
americanbankingnews.com logoShort Interest in Anthera Pharmaceuticals Inc (ANTH) Expands By 13.9%
www.americanbankingnews.com - May 18 at 4:22 PM
americanbankingnews.com logoAnthera Pharmaceuticals Inc (ANTH) Expected to Post Q2 2017 Earnings of ($1.08) Per Share
www.americanbankingnews.com - May 17 at 8:08 AM
reuters.com logoBRIEF-Anthera announces first patient screened in result pivotal phase 3 clinical study of sollpura
www.reuters.com - May 16 at 3:38 PM
rttnews.com logoAKBA Abuzz, ANTH On Track For RESULT, IMUC Faces Cash Crunch, IONS Falls
www.rttnews.com - May 16 at 3:38 PM
globenewswire.com logoAnthera Announces First Patient Screened in RESULT Pivotal ... - GlobeNewswire (press release)
globenewswire.com - May 16 at 7:56 AM
finance.yahoo.com logoAnthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical Study of Sollpura
finance.yahoo.com - May 16 at 7:56 AM
americanbankingnews.com logoAnthera Pharmaceuticals Inc (ANTH) Receives Hold Rating from Jefferies Group LLC
www.americanbankingnews.com - May 15 at 9:34 PM
americanbankingnews.com logoAnthera Pharmaceuticals Inc (ANTH) Releases Earnings Results, Misses Estimates By $0.56 EPS
www.americanbankingnews.com - May 11 at 5:30 PM
nasdaq.com logoAnthera Pharmaceuticals Provides Business Update and Reports 2017 First Quarter Financial Results - Nasdaq
www.nasdaq.com - May 11 at 1:47 AM
globenewswire.com logoAnthera Pharmaceuticals Provides Business Update and Reports 2017 First Quarter Financial Results - GlobeNewswire (press release)
globenewswire.com - May 10 at 8:46 PM
finance.yahoo.com logoAnthera Pharmaceuticals Provides Business Update and Reports 2017 First Quarter Financial Results
finance.yahoo.com - May 10 at 8:46 PM
finance.yahoo.com logoAnthera reports 1Q loss
finance.yahoo.com - May 10 at 8:46 PM
americanbankingnews.com logo Brokerages Anticipate Anthera Pharmaceuticals Inc (ANTH) Will Post Earnings of -$1.39 Per Share
www.americanbankingnews.com - May 9 at 12:22 AM
americanbankingnews.com logoZacks Investment Research Downgrades Anthera Pharmaceuticals Inc (ANTH) to Hold
www.americanbankingnews.com - May 8 at 5:28 PM
americanbankingnews.com logoAnthera Pharmaceuticals Inc (ANTH) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - May 5 at 11:12 PM
americanbankingnews.com logoAnthera Pharmaceuticals Inc (ANTH) Set to Announce Earnings on Monday
www.americanbankingnews.com - May 5 at 10:47 PM
americanbankingnews.com logoAnthera Pharmaceuticals Inc (ANTH) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - May 5 at 10:23 PM
americanbankingnews.com logoSomewhat Positive Media Coverage Unlikely to Impact Anthera Pharmaceuticals (ANTH) Share Price
www.americanbankingnews.com - May 1 at 11:46 AM
streetinsider.com logoAnthera Pharma (ANTH) Plans 1-for-8 Reverse Split of Stock
www.streetinsider.com - April 29 at 2:34 AM
reuters.com logoBRIEF-Anthera Pharmaceuticals announces 1-for-8 reverse split of stock
www.reuters.com - April 29 at 2:34 AM
finance.yahoo.com logoAnthera Pharmaceuticals Announces 1-for-8 Reverse Split of Stock - Yahoo Finance
finance.yahoo.com - April 28 at 4:31 PM
globenewswire.com logoAnthera Pharmaceuticals Announces 1-for-8 Reverse Split of Stock - GlobeNewswire (press release)
globenewswire.com - April 28 at 4:31 PM
finance.yahoo.com logoAnthera Pharmaceuticals Announces 1-for-8 Reverse Split of Stock
finance.yahoo.com - April 28 at 4:31 PM
americanbankingnews.com logoAnthera Pharmaceuticals Inc (ANTH) Short Interest Update
www.americanbankingnews.com - April 27 at 7:06 AM
americanbankingnews.com logoAnthera Pharmaceuticals (ANTH) Getting Somewhat Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 26 at 3:18 PM
americanbankingnews.com logoAnthera Pharmaceuticals Inc (ANTH) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 25 at 5:45 PM
americanbankingnews.com logoAnthera Pharmaceuticals (ANTH) Receiving Somewhat Critical Press Coverage, Report Shows
www.americanbankingnews.com - April 23 at 8:21 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Anthera Pharmaceuticals Inc (ANTH) to Announce -$0.19 EPS
www.americanbankingnews.com - April 18 at 11:20 AM
americanbankingnews.com logoVery Positive Media Coverage Extremely Likely to Effect Anthera Pharmaceuticals (ANTH) Stock Price
www.americanbankingnews.com - April 16 at 7:58 AM
americanbankingnews.com logoAnthera Pharmaceuticals Inc (ANTH) Forecasted to Earn FY2021 Earnings of $0.07 Per Share
www.americanbankingnews.com - April 14 at 2:56 PM
finance.yahoo.com logoANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study
finance.yahoo.com - April 11 at 3:32 PM
finance.yahoo.com logoANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study
finance.yahoo.com - April 11 at 3:32 PM
finance.yahoo.com logoAnthera Announces Completion of Dosing in the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy
finance.yahoo.com - April 10 at 3:34 PM
finance.yahoo.com logoANTH SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Anthera Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of April 17, 2017
finance.yahoo.com - April 10 at 3:34 PM
finance.yahoo.com logoDEADLINE ALERT: Brower Piven Reminds Investors Of The Upcoming Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Anthera Pharmaceuticals, Inc. To Contact The Firm
finance.yahoo.com - April 8 at 11:12 AM
finance.yahoo.com logoETFs with exposure to Anthera Pharmaceuticals, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 8:37 PM
nasdaq.com logoRPT-BUZZ-U.S. STOCKS ON THE MOVE-Lululemon, Conocophillips, Interpace, Corbus Pharma, Anthera Pharma - Nasdaq
www.nasdaq.com - March 31 at 3:40 PM
nasdaq.com logoRPT-BUZZ-U.S. STOCKS ON THE MOVE-Lululemon, Conocophillips, Interpace, Corbus Pharma, Anthera Pharma - Nasdaq
www.nasdaq.com - March 31 at 3:40 PM
biz.yahoo.com logoANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 31 at 3:40 PM
biz.yahoo.com logoANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 31 at 3:40 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Complaint to Recover Losses Suffered by Investors in Anthera Pharmaceuticals, Inc. -- Lead Plaintiff Deadline of April 17, 2017 -- ANTH
finance.yahoo.com - March 31 at 3:40 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Complaint to Recover Losses Suffered by Investors in Anthera Pharmaceuticals, Inc. -- Lead Plaintiff Deadline of April 17, 2017 -- ANTH
finance.yahoo.com - March 31 at 3:40 PM
americanbankingnews.com logoAnthera Pharmaceuticals Inc (ANTH) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 31 at 2:06 PM
investopedia.com logoAnthera's Sollpura On Par With Pancreaze (ANTH)
www.investopedia.com - March 30 at 3:58 PM
us.rd.yahoo.com logoAnthera's Sollpura On Par With Pancreaze Study
us.rd.yahoo.com - March 30 at 3:58 PM
streetinsider.com logoAnthera Pharma (ANTH) Reports Positive Results from the Extension Period of SOLUTION Study of Sollpura
www.streetinsider.com - March 30 at 1:45 AM

Social

Chart

Anthera Pharmaceuticals (ANTH) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff